{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:28Z","timestamp":1793943988414,"version":"4.8.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12368031"],"award-info":[{"award-number":["GR-2018-12368031"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-06023-8","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:39:43Z","timestamp":1735846783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PD-L1 and IFN-\u03b3 modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)"],"prefix":"10.1186","volume":"23","author":[{"given":"Stefania","family":"Angelicola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Frascino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Scalambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sofia","family":"Semprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Maria","family":"Pittino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Siracusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Candida","family":"Chillico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Noia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Turato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"De Siervi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lescai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ciavattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lopatriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"De Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Iamele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Altimari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gruppioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Rossato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier-Luigi","family":"Lollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-4895","authenticated-orcid":false,"given":"Arianna","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"6023_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. The Lancet. 2021;398:535\u201354.","journal-title":"The Lancet"},{"key":"6023_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"6023_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11912-021-01124-9","volume":"23","author":"A De Giglio","year":"2021","unstructured":"De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The landscape of immunotherapy in advanced NSCLC: driving beyond PD-1\/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines). Curr Oncol Rep. 2021;23:126.","journal-title":"Curr Oncol Rep"},{"key":"6023_CR4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044\u201360.","journal-title":"Curr Oncol"},{"key":"6023_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.877594","volume":"12","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol. 2022;12: 877594.","journal-title":"Front Oncol"},{"key":"6023_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385\u201396.","journal-title":"Ann Oncol"},{"key":"6023_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020309","volume":"13","author":"S Angelicola","year":"2021","unstructured":"Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, et al. IFN-\u03b3 and CD38 in hyperprogressive cancer development. Cancers. 2021;13:1\u201325.","journal-title":"Cancers"},{"key":"6023_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx376.006","volume":"28","author":"AK Singavi","year":"2017","unstructured":"Singavi AK, Menon S, Kilari D, Alqwasmi A, Ritch PS, Thomas JP, et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)\u2014analysis of somatic alterations (SAs). Ann Oncol. 2017;28: v405.","journal-title":"Ann Oncol"},{"key":"6023_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res. 2019;25:989\u201399.","journal-title":"Clin Cancer Res"},{"key":"6023_CR10","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116:9999\u201310008.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6023_CR11","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.21037\/tlcr-22-163","volume":"11","author":"F Ruzzi","year":"2022","unstructured":"Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, et al. ADK-VR2, a cell line derived from a treatment-na\u00efve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. Transl Lung Cancer Res. 2022;11:2216\u201329.","journal-title":"Transl Lung Cancer Res"},{"key":"6023_CR12","unstructured":"FastQC. http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/. Accessed 5 March 2024."},{"key":"6023_CR13","unstructured":"RSEM. https:\/\/github.com\/deweylab\/RSEM. Accessed 5 March 2024."},{"key":"6023_CR14","doi-asserted-by":"crossref","unstructured":"Yu G, Wang LG, Hu E, Luo X, Chen M, Dall\u2019Olio G, et al. ClusterProfiler. https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/clusterProfiler.html. Accessed 5 March 2024.","DOI":"10.1016\/j.xinn.2024.100722"},{"key":"6023_CR15","doi-asserted-by":"publisher","first-page":"54444","DOI":"10.18632\/oncotarget.17088","volume":"8","author":"A Palladini","year":"2017","unstructured":"Palladini A, Nicoletti G, Lamolinara A, Dallora M, Balboni T, Ianzano ML, et al. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget. 2017;8:54444\u201358.","journal-title":"Oncotarget"},{"issue":"16","key":"6023_CR16","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/bcr3602","volume":"23","author":"C De Giovanni","year":"2014","unstructured":"De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 2014;23(16):R10.","journal-title":"Breast Cancer Res"},{"key":"6023_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64.","journal-title":"J Hematol Oncol"},{"key":"6023_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6023_CR19","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1038\/ncomms9698","volume":"6","author":"YM Oh","year":"2015","unstructured":"Oh YM, Park HB, Shin JH, Lee JE, Park HY, Kho DH, et al. Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. Nat Commun. 2015;6:8698.","journal-title":"Nat Commun"},{"key":"6023_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell. 2020;37:324-339.e8.","journal-title":"Cancer Cell"},{"key":"6023_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8:49.","journal-title":"Biomark Res"},{"key":"6023_CR22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","volume":"31","author":"Y Tang","year":"2024","unstructured":"Tang Y, Pu X, Yuan X, Pang Z, Li F, Wang X. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential. Cancer Gene Ther. 2024;31:961\u20139.","journal-title":"Cancer Gene Ther"},{"key":"6023_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","volume":"3","author":"D Escors","year":"2018","unstructured":"Escors D, Gato-Ca\u00f1as M, Zuazo M, Arasanz H, Garc\u00eda-Granda MJ, Vera R, et al. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26.","journal-title":"Signal Transduct Target Ther"},{"key":"6023_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020;11: 568931.","journal-title":"Front Immunol"},{"key":"6023_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5483\/BMBRep.2021.54.1.241","volume":"54","author":"P Yadollahi","year":"2021","unstructured":"Yadollahi P, Jeon YK, Ng WL, Choi I. Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity. BMB Rep. 2021;54:12\u201320.","journal-title":"BMB Rep"},{"key":"6023_CR26","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms24076420","volume":"24","author":"D Alkaabi","year":"2023","unstructured":"Alkaabi D, Arafat K, Sulaiman S, Al-Azawi AM, Attoub S. PD-1 independent role of PD-L1 in triple-negative breast cancer progression. Int J Mol Sci. 2023;24:6420.","journal-title":"Int J Mol Sci"},{"key":"6023_CR27","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/jnci\/djad126","volume":"115","author":"C Nieto","year":"2023","unstructured":"Nieto C, Miller B, Alzofon N, Chimed T, Himes J, Joshi M, et al. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma. J Natl Cancer Inst. 2023;115:1392\u2013403.","journal-title":"J Natl Cancer Inst"},{"key":"6023_CR28","doi-asserted-by":"publisher","first-page":"2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016;2016:2087204.","journal-title":"Stem Cells Int"},{"key":"6023_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40: e108647.","journal-title":"EMBO J"},{"key":"6023_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccell.2022.12.008","volume":"41","author":"G Li","year":"2023","unstructured":"Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023;41:304-322.e7.","journal-title":"Cancer Cell"},{"key":"6023_CR31","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.7150\/thno.67409","volume":"12","author":"C Gaiteiro","year":"2022","unstructured":"Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, et al. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022;12:3150\u201377.","journal-title":"Theranostics"},{"key":"6023_CR32","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biom11121850","volume":"11","author":"MH Mesrati","year":"2021","unstructured":"Mesrati MH, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021;11:1850.","journal-title":"Biomolecules"},{"key":"6023_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"6023_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/cas.12406","volume":"105","author":"K Tamai","year":"2014","unstructured":"Tamai K, Nakamura M, Mizuma M, Mochizuki M, Yokoyama M, Endo H, et al. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci. 2014;105:667\u201374.","journal-title":"Cancer Sci"},{"key":"6023_CR35","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. PNAS. 2020;117:6640\u201350.","journal-title":"PNAS"},{"key":"6023_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, et al. PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11:506.","journal-title":"Cell Death Dis"},{"key":"6023_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","volume":"41","author":"L Gao","year":"2019","unstructured":"Gao L, Guo Q, Li X, Yang X, Ni H, Wang T, et al. MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine. 2019;41:395\u2013407.","journal-title":"EBioMedicine"},{"key":"6023_CR38","doi-asserted-by":"publisher","first-page":"1729299","DOI":"10.1080\/2162402X.2020.1729299","volume":"9","author":"FA Mansour","year":"2020","unstructured":"Mansour FA, Al-Mazrou A, Al-Mohanna F, Al-Alwan M, Ghebeh H. PD-L1 is overexpressed on breast cancer stem cells through notch3\/mTOR axis. Oncoimmunology. 2020;9:1729299.","journal-title":"Oncoimmunology"},{"key":"6023_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-020-01648-1","volume":"39","author":"W Hong","year":"2020","unstructured":"Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4\/ let-7 miRNA\/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39:149.","journal-title":"J Exp Clin Cancer Res"},{"key":"6023_CR40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","volume":"80","author":"T Kong","year":"2020","unstructured":"Kong T, Ahn R, Yang K, Zhu X, Fu Z, Morin G, et al. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res. 2020;80:444\u201357.","journal-title":"Cancer Res"},{"key":"6023_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12935-020-01671-4","volume":"20","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wang H, Wang X, Zhao C, Wang H. CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell Int. 2020;20:583.","journal-title":"Cancer Cell Int"},{"key":"6023_CR42","doi-asserted-by":"publisher","unstructured":"Subhadarshini S, Sahoo S, Debnath S, Somarelli JA, Kumar Jolly M. Dynamical modelling of proliferative-invasive plasticity and IFN\u03b3 signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity. bioRxiv. 2023; https:\/\/doi.org\/10.1101\/2023.01.09.523355.","DOI":"10.1101\/2023.01.09.523355"},{"key":"6023_CR43","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302461","volume":"7","author":"H Cao","year":"2024","unstructured":"Cao H, Xiang Y, Zhang S, Chao Y, Guo J, Aurich T, et al. PD-L1 regulates inflammatory programs of macrophages from human pluripotent stem cells. Life Sci Alliance. 2024;7: e202302461.","journal-title":"Life Sci Alliance"},{"key":"6023_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109:43\u201353.","journal-title":"Cancer Sci"},{"key":"6023_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/2326-6066.CIR-22-0056","volume":"11","author":"T Han","year":"2023","unstructured":"Han T, Wang X, Shi S, Zhang W, Wang J, Wu Q, et al. Cancer cell resistance to IFN\u03b3 can occur via enhanced double-strand break repair pathway activity. Cancer Immunol Res. 2023;11:381\u201398.","journal-title":"Cancer Immunol Res"},{"key":"6023_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"6023_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375\u201386.","journal-title":"Nat Rev Immunol"},{"key":"6023_CR48","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20:1574\u201383.","journal-title":"Nat Immunol"},{"key":"6023_CR49","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540-1554.e12.","journal-title":"Cell"},{"key":"6023_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42:209-224.e9.","journal-title":"Cancer Cell"},{"key":"6023_CR51","doi-asserted-by":"crossref","unstructured":"Majoros A, Platanitis E, Kernbauer-H\u00f6lzl E, Rosebrock F, M\u00fcller M, Decker T. Canonical and non-canonical aspects of JAK\u2013STAT signaling: lessons from interferons for cytokine responses. Front Immunol. 2017;8.","DOI":"10.3389\/fimmu.2017.00029"},{"key":"6023_CR52","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"6023_CR53","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.4049\/jimmunol.1203510","volume":"191","author":"SJ Kearney","year":"2013","unstructured":"Kearney SJ, Delgado C, Eshleman EM, Hill KK, O\u2019Connor BP, Lenz LL. Type I IFNs downregulate myeloid cell IFN-\u03b3 receptor by inducing recruitment of an early growth response 3\/NGFI-A binding protein 1 complex that silences ifngr1 transcription. J Immunol. 2013;191:3384\u201392.","journal-title":"J Immunol"},{"key":"6023_CR54","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201900447","volume":"2","author":"WJ Crisler","year":"2019","unstructured":"Crisler WJ, Eshleman EM, Lenz LL. Ligand-induced IFNGR1 down-regulation calibrates myeloid cell IFN\u03b3 responsiveness. Life Sci Alliance. 2019;2: e201900447.","journal-title":"Life Sci Alliance"},{"key":"6023_CR55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1471-2407-8-260","volume":"8","author":"EW Robbins","year":"2008","unstructured":"Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer. 2008;8:260.","journal-title":"BMC Cancer"},{"key":"6023_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1089\/jir.2014.0188","volume":"35","author":"CT Ng","year":"2015","unstructured":"Ng CT, Fong LY, Sulaiman MR, Moklas MAM, Yong YK, Hakim MN, et al. Interferon-gamma increases endothelial permeability by causing activation of p38 MAP kinase and actin cytoskeleton alteration. J Interferon Cytokine Res. 2015;35:513\u201322.","journal-title":"J Interferon Cytokine Res"},{"key":"6023_CR57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tem.2022.04.009","volume":"33","author":"V Vella","year":"2022","unstructured":"Vella V, De Francesco EM, Bonavita E, Lappano R, Belfiore A. IFN-I signaling in cancer: the connection with dysregulated Insulin\/IGF axis. Trends Endocrinol Metab. 2022;33:569\u201386.","journal-title":"Trends Endocrinol Metab"},{"key":"6023_CR58","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner S, Cords L, Kasser S, Freiberger SN, Kreutzer S, Toussaint NC, et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat Commun. 2023;14:5154.","journal-title":"Nat Commun"},{"key":"6023_CR59","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","volume":"79","author":"M Song","year":"2019","unstructured":"Song M, Ping Y, Zhang K, Yang L, Li F, Zhang C, et al. Low-dose IFN\u03b3 induces tumor cell stemness in tumor microenvironment of non\u2013small cell lung cancer. Cancer Res. 2019;79:3737\u201348.","journal-title":"Cancer Res"},{"key":"6023_CR60","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.stem.2023.05.007","volume":"30","author":"L Beziaud","year":"2023","unstructured":"Beziaud L, Young CM, Alonso AM, Norkin M, Minafra AR, Huelsken J. IFN\u03b3-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. Cell Stem Cell. 2023;30:818-831.e6.","journal-title":"Cell Stem Cell"},{"key":"6023_CR61","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2023","unstructured":"P\u00e9rez-Gonz\u00e1lez A, B\u00e9vant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4:1063\u201382.","journal-title":"Nat Cancer"},{"key":"6023_CR62","doi-asserted-by":"crossref","unstructured":"Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.1023177"},{"key":"6023_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2105-14-41","volume":"14","author":"Y Qi","year":"2013","unstructured":"Qi Y, Huang Y, Wang H, Zhang Y, Bao Y, Sun L, et al. Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling. BMC Bioinformatics. 2013;14:41.","journal-title":"BMC Bioinformatics"},{"key":"6023_CR64","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL, Nairism\u00e4gi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood. 2018;132:1146\u201358.","journal-title":"Blood"},{"key":"6023_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000285","volume":"8","author":"W Zhang","year":"2020","unstructured":"Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer. 2020;8: e000285.","journal-title":"J Immunother Cancer"},{"key":"6023_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","volume":"25","author":"N Chuangchot","year":"2023","unstructured":"Chuangchot N, Jamjuntra P, Yangngam S, Luangwattananun P, Thongchot S, Junking M, et al. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways. Breast Cancer Res. 2023;25:86.","journal-title":"Breast Cancer Res"},{"key":"6023_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"6023_CR68","doi-asserted-by":"publisher","first-page":"19552","DOI":"10.1038\/s41598-023-46628-5","volume":"13","author":"J Ar\u00e9valo","year":"2023","unstructured":"Ar\u00e9valo J, Campoy I, Dur\u00e1n M, Nemours S, Areny A, Vall-Palomar M, et al. STAT3 phosphorylation at serine 727 activates specific genetic programs and promotes clear cell renal cell carcinoma (ccRCC) aggressiveness. Sci Rep. 2023;13:19552.","journal-title":"Sci Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-06023-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:06:25Z","timestamp":1735848385000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-06023-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6023"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-06023-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"3 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Human samples were collected after the patient gave her informed consent. The protocol was approved by the Ethics Committee Center Emilia-Romagna Region, Italy (GR-2018-12368031). Human samples and metadata including relevant clinical data were de-identified before being shared between laboratories involved in this study. All animal procedures were performed in accordance with European directive 2010\/63\/UE and Italian Law (No. DL26\/2014). Experimental protocols were reviewed and approved by the institutional animal care and use committee of the University of Bologna and by the Italian Ministry of Health with letter 32\/2020-PR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Andrea Ardizzoni received research grants from Celgene, Bristol-Myers Squibb, Ipsen, and Roche; and honoraria for advisory roles from Bristol-Myers Squibb, Merck Sharp & Dohme, ROCHE, AstraZeneca, and Eli Lilly outside of the submitted work. Dr. Francesco Gelsomino received honoraria or personal fees for the advisory role or consulting from Eli Lilly, Novartis, AstraZeneca, Pfizer, Regeneron and Bristol-Myers Squibb outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}